Cargando…

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

Relugolix, the first orally active, nonpeptide gonadotropin‐releasing hormone receptor antagonist, is approved in the United States and the European Union for the treatment of adult patients with advanced prostate cancer. The recommended dosing regimen is a 360‐mg loading dose followed by a 120‐mg d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Tien‐Yi, Pierrillas, Philippe Bernard, Lin, Yu‐Wei, de Greef, Rik, Zandvliet, Anthe Suzanne, Schindler, Emilie, Migoya, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091729/ https://www.ncbi.nlm.nih.gov/pubmed/36073238 http://dx.doi.org/10.1002/cpt.2743

Ejemplares similares

A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
por: Lukes, Andrea, et al.
Publicado: (2023)

Translation of the efficacy of antibody–drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88
por: Li, Qiaoning, et al.
Publicado: (2023)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis
por: Arjona Ferreira, Juan C., et al.
Publicado: (2022)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

Characterization of prickle isoform-specific pk (pk1) and pk (sple1) mutations in Drosophila melanogaster
por: Lilienthal, Anthony J, et al.
Publicado: (2022)

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
por: Zhang, Nan, et al.
Publicado: (2016)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature-Based Meta-Analyses
por: Vargo, R, et al.
Publicado: (2014)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
por: Akashita, Gaku, et al.
Publicado: (2015)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae
por: Huang, Zilong, et al.
Publicado: (2020)

S17.3 PK/PD in the treatment of hospital-acquired pneumonia
Publicado: (2005)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia
por: Zhou, Yingjie, et al.
Publicado: (2022)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

Increasing interest in PK and PD studies has many advantages for anesthesiologists
por: Woo, Young-Cheol
Publicado: (2011)

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
por: Smith, Alison, et al.
Publicado: (2016)

Traditional PK-PD Indices for Efficacy – Can We Do Better?
por: Lakota, Elizabeth A, et al.
Publicado: (2017)

Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery
por: Mrsny, Randall J., et al.
Publicado: (2021)

P267 Candida in the biliary tract: extrapolative PK PD considerations
por: Rege, Sujata, et al.
Publicado: (2022)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Meropenem PK/PD Variability and Renal Function: “We Go Together”
por: Angelini, Jacopo, et al.
Publicado: (2023)

Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Complete Genome Sequence of the Pokeweed Mosaic Virus (PkMV)-New Jersey Isolate and Its Comparison to PkMV-MD and PkMV-PA
por: Di, Rong
Publicado: (2016)

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
por: De La Cerda, Jose, et al.
Publicado: (2023)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs
por: Li, Xiao-dong, et al.
Publicado: (2019)

Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab
por: Tiwari, Abhinav, et al.
Publicado: (2019)

PK/PD integration of florfenicol alone and in combination with doxycycline against Riemerella anatipestifer
por: Zhang, Huilin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_108bfc7341rb1cv6v5djlehg0i